XML 126 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration and license agreements (Tables)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Allocation of total transaction price and unsatisfied transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2024 (in thousands):
Transaction
Price
Allocated
Transaction
Price
Unsatisfied
Performance obligations:
Research and development targets$16,688 $12,700 
Option rights2,376 2,376 
Total$19,064 $15,076 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements was as follows (in thousands):
Years Ended December 31,
20242023
Revenue from collaboration agreements:
MKDG Agreement$7,304 $— 
Merck Agreement3,979 — 
Betta Agreement 3,415 — 
Roche Agreement3,988 9,063 
Biogen Agreement16,898 10,623 
Calico Agreement— 1,070 
Total revenue from collaboration agreements$35,584 $20,756 
Schedule of financial information related to collaboration and license agreements
Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2024 (in thousands):
Accounts
Receivable
Deferred
Revenue,
Current
Deferred
Revenue,
Net of Current
Deferred
Revenue,
Total
Supplemental information:
MKDG Agreement$2,064 5,396 7,977 $13,373 
Merck Agreement— 3,441 2,581 6,022 
Betta Agreement1,038 4,038 11,243 15,281 
Roche Agreement— 5,837 6,656 12,493 
Total$3,102 $18,712 $28,457 $47,169 
Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2023 (in thousands):
Accounts
Receivable
Deferred
Revenue,
Current
Deferred
Revenue,
Net of Current
Deferred
Revenue,
Total
Supplemental information:
Merck Agreement$10,000 $8,000 $2,000 $10,000 
Roche Agreement— 2,667 11,814 14,481 
Betta Agreement1,799 4,000 8,000 12,000 
Biogen Agreement— 804 — $804 
Total$11,799 $15,471 $21,814 $37,285 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements are (in thousands):
Years Ended December 31,
20242023
Revenue recognized that was included in the contract liability at the beginning of the period$12,184 $20,185 
Revenue recognized from performance obligations fully or partially satisfied in previous periods— 43